Delaware Group State Tax-Free Income Trust has released its latest financial report, revealing total assets of approximately $384 million as of August 31, 2026. This update is significant as it reflects the trust's investment strategies and performance in the municipal bond sector, particularly focusing on Pennsylvania.
The trust, incorporated in Delaware and based in Philadelphia, primarily invests in tax-free municipal bonds, aiming to provide investors with income that is exempt from federal taxes. The recent filing, submitted on October 29, 2026, under the NPORT-P form, provides insights into the fund's financial health and investment focus.
Background
Delaware Group State Tax-Free Income Trust operates under the Central Index Key (CIK) 0000201670. The trust's primary investment strategy revolves around tax-free income generation through municipal bonds, specifically those issued within Pennsylvania. It has been active in filing various forms, including N-PX and N-CSR, with its most recent filings indicating a consistent approach to reporting its financials.
What the Filing Says
The filing indicates that as of August 31, 2026, the trust's total assets stood at $384,269,266.13, with total liabilities of $2,855,125.72, resulting in net assets of $381,414,140.41. This reflects a solid financial position for the trust, which continues to focus on investments in Pennsylvania municipal bonds.
Impact
This update may influence a variety of stakeholders, including current and potential investors, who are interested in tax-free income opportunities. Additionally, it may affect other competitors in the municipal bond sector, as they assess their own strategies in light of the trust's performance.
What's Next
The filing does not say what happens next, leaving stakeholders to anticipate future updates and potential changes in investment strategy or market conditions.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






